Emergency Critical Care

Clinical trials for Emergency Critical Care specialty

  • Description

    The goal of this study is to determine if TK isoenzymes are good biomarkers for the early detection of HSA in dogs and to identify a threshold for detecting HSA from the presence of TK isoenzymes.

    HSA is a malignant and rapidly growing cancer that is difficult to detect. HSA is a tumor derived from blood vessels, and thus the tumor is filled with blood. A frequent cause of death from HSA is the rupturing of the tumor, causing the patient to rapidly hemorrhage to death. HSA is common in dogs, and more so in certain breeds of dogs such as German Shepherds and Golden Retrievers. Dogs with HSA rarely show clinical signs until the tumor has become very large and has metastasized. Typically, clinical signs are due to hypovolemia after the tumor ruptures, causing severe bleeding. Owners of the affected dogs often discover that the dog has HSA only after the animal has collapsed secondary to bleeding. The HSA tumor often appears on the spleen, right side of the heart or liver.

    There are currently no commercially viable screening mechanisms for detecting HSA in dogs. Most dogs present with HSA as emergencies and major decisions about treatment must be made without a definitive diagnosis. A screening test that would allow the detection of HSA would be very valuable in the planning of treatment and earlier detection of the disease. Preliminary data in dogs suggests that TK is significantly increased in dogs with some types of cancer, specifically HSA and thus TK may be useful in detecting, staging and monitoring disease in dogs with HSA.

    Inclusion Criteria

    Any dog (any age, sex or breed) with a hemoabdomen that undergoes exploratory surgery.

    Exclusion Criteria

    Dogs with pre-existing, previously diagnosed neoplastic conditions other than hemangiosarcoma will be excluded.

    Client Benefits

    There are no direct benefits to the client. The indirect benefit is that this research will aid in the development of a point-of-care test for the diagnosis of hemangiosarcoma in dogs which will help owners of dogs with hemoabdomen make decisions regarding the best management for their dogs.

    Contact Information

    Dr. Claire Sharp
    Phone: (508) 839-5302

  • Title: Evaluating hypercoagulability in dogs with brachycephalic airway syndrome: similarity to human obstructive sleep apnea.


    The primary purpose of the study is to determine whether English Bulldogs are more hypercoagulable than non-brachycephalic dogs by running a series of coagulation tests. We are also interested in determining if C-reactive protein, a marker of inflammation and cardiovascular risk, is elevated in English Bulldogs as it is in humans with obstructive sleep apnea.

    Inclusion Criteria:

    English Bulldogs that have not undergone upper airway surgery and are currently exhibiting clinical signs consistent with the brachycephalic airway syndrome as documented by their owner (loud upper airway noise, snoring).

    English Bulldogs that are between 2 and 8 years of age, any sex or weight.

    Exclusion Criteria:

    English Bulldogs known to have a condition that will affect coagulation status, such as neoplasia, hemolytic anemia or thrombocytopenia.

    English Bulldogs taking medication that may affect its coagulation parameters, such as non-steroidal anti-inflammatory drugs, warfarin, low molecular weight heparin, clopidogrel, aspirin, or prednisone.

    English Bulldogs that have had surgical correction of their upper airway abnormalities (ie. Palatoplasty and rhinoplasty) to resolve/improve brachycephalic airway signs.

    Client Benefits:

    The study will cover the costs of routine bloodwork as well as coagulation tests and C-reactive protein analysis. Your dog’s participation will also allow us to gain information which will help in the treatment of other dogs with this condition.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu

  • Description:

    Recent studies in the human literature have documented that quicker lactate clearance is associated with improved survival in trauma patients.  It is currently unknown if a similar trend exists in canine trauma patients.  Our goal is to examine lactate clearance in canine trauma patients; samples will be taken at admission, and 2 and 4 hours after admission.

    The purpose of the study is to determine whether lactate predicts how well dogs that have experienced trauma will do overall and whether or not they will need blood transfusions.

    Inclusion Criteria:

    Dogs presenting with trauma (any kind) AND a lactate of ≥4 mmol/L at time of admission.  Prior treatment is allowed.

     Exclusion Criteria:

    Dogs presenting with trauma but having a lactate < 4 will be excluded; dogs that have a physiologic or pathophysiologic cause of hyperlactatemia that is not related to trauma will be excluded.  Such patients could include those with neoplasia, those with hepatic disease, those who are taking steroids, or those which have had a seizure in the 6 hours prior to presentation.

     Client  Benefits:

    The study will cover the costs of the three blood tests. Your pet’s participation will also allow us to gain information which will help in the diagnosis/management/treatment of other dogs that have experienced trauma

     Contact information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu